Purpose of Review Genetic factors contribute to the etiology of anorexia nervosa (AN). This review synthesizes the current state of knowledge about the genetic etiology of AN, provides directions for future research, and discusses clinical implications for this research. Recent Findings Candidate gene meta-analyses indicate serotonin genes may be involved in the genetic etiology of AN. Three genome-wide association studies have been conducted and one genome-wide significant locus was identified. Crossdisorder analyses suggest shared genetic risk between AN and several psychiatric, educational, and medical phenotypes. Summary Much has been learned about the genetic etiology of AN over the past 3 decades. However, to fully understand the genetic architecture, we must consider all aspects including common variation, cross-disorder analysis, rare variation, copy number variation, and gene-environment interplay. Findings have important implications for the development of treatment and prevention approaches and for how AN, and psychiatric and medical diseases in general, are conceptualized.
Introduction
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), anorexia nervosa (AN) is characterized by a body weight that is less than minimally expected for age, sex, developmental trajectory, and physical health, an intense fear of gaining weight, and body image disturbance [1] . The lifetime prevalence of DSM-5 AN is approximately 4% [2] , and AN is more common in females compared with males [3] . AN has the highest mortality rate of any psychiatric disorder [4] and is associated with high rates of medical complications and psychiatric comorbidities [3] . Despite the devastating consequences of AN, the etiology is still unclear. However, over the past 3 decades, research has established that genetic factors contribute to the etiology of AN. The aim of this review is to provide readers a brief overview of the history of genetic research as it pertains to AN, the current state of knowledge about the genetic etiology of AN, and the implications of this research. An exhaustive review of all genetic studies is not our aim; these have been reported elsewhere [5•, 6-7] . Here, we focus on historical studies and areas of research that have added to our knowledge about the genetic architecture of AN along with reports using current genetic methodologies to provide the reader with an accurate portrayal of our contemporary understanding of the genetic etiology of AN.
indicating there is a significant genetic contribution to this familial association. Replicated heritability estimates for AN have ranged between 48 and 74% depending on the definition of AN used [5•] . Twin studies have also suggested there is shared genetic risk between AN and multiple psychiatric phenotypes including other eating disorders [9] , obsessivecompulsive disorder [10] , major depression, and suicide attempts [11] . Although family and twin studies provided initial evidence of the role of genetic factors in AN, these methods cannot identify which genetic variants are involved in risk.
Early molecular genetic techniques used to identify genes involved in risk for AN included linkage studies and candidate gene studies (Table 1) . Unfortunately, these methodologies revealed very little about precise genetic contributions to AN. Too few linkage studies were conducted and too few follow-ups were completed to draw definitive conclusions about the meaning of their findings. In contrast, hundreds of AN candidate gene studies have been conducted [5•, 6-7] ; however, findings are hindered by small sample sizes, low power, and lack of replication. Thus, few conclusions can be drawn about the genes involved in risk for AN based on candidate gene studies. In the last decade, meta-analyses were conducted in an effort to clarify the fragmented candidate gene literature for the most promising single nucleotide polymorphisms (SNPs; variation at a single position in a DNA sequence among individuals). This included a serotonin receptor and transporter gene (HTR2A, 5-HTT), a COMT polymorphism (Val158Met), and a BDNF polymorphism (Val66Met).
Meta-analysis results indicated a significant association between HTR2A and AN. Specifically, the A allele of the −1438G/A polymorphism was significantly more common in individuals with AN compared with controls [12, 13] . Two meta-analyses also indicated that the short allele of 5-HTTLPR, a 5-HTT polymorphism, increased risk for AN compared with long allele carriers [14, 15] . However, a meta-analysis conducted in 2016 did not replicate these results [16•] . Although some candidate gene studies showed a significant association between Val158Met and Val66Met and AN, meta-analyses indicated no significant association between these polymorphisms and AN risk [17, 18] .
Undoubtedly, family, twin, linkage, and candidate gene studies paved the way for understanding the genetic architecture of AN. Several lessons were also learned from the inconsistent and inconclusive results obtained from linkage and candidate gene studies. This includes the limitations of a small sample size, heterogeneous methodologies, failure to account for multiple testing, and that a small set of candidate genes is not a valid model to explain the etiology of AN. Like other psychiatric disorders, AN is polygenic, whereby many genes of small effect contribute to its development. Thus, linkage and candidate gene studies are now considered out-of-date methodologies to identify genes involved in disease risk. Due to recent advances in technology and the decreased cost of genomic experiments, the psychiatric genetics field has moved on to more advanced methodologies such as genome-wide association studies (GWAS) and cross- Table 2 ), but additional GWAS are underway [22] . The first two GWAS of AN conducted did not find any genomewide significant results [19, 20•] . However, Boraska and colleagues (2014) [20•] observed that intronic variants in SOX2OT and PPP3CA were suggestively associated with AN, which have been previously associated with Alzheimer's disease. Despite the lack of genome-wide significant results, a majority of the replication results were in the same direction as the discovery results-a finding unlikely to be due to chance [20•] . A smaller GWAS of 184 cases with bipolar disorder and a comorbid eating disorder also found suggestive hits within SOX2OT [23] . The largest and most rigorous GWAS to date included approximately 4000 AN cases and 11,000 controls [21••] . One locus on chromosome 12 (12q13.2), which included six genes (IKZF4, RPS26, ERBB3, PA2G4, RPL41, and ZC3H10), reached genome-wide significance (p < 5 × 10
) and had a genome-wide common variant heritability of 20%. The top SNP was in the ERBB3 gene. This SNP is in high linkage disequilibrium (i.e., non-random association of alleles at different loci) with a SNP associated with rheumatoid arthritis and type 1 diabetes. Previous associations with this region have also been reported with several other autoimmune diseases such as asthma, vitiligo, and alopecia areata. Interestingly, this GWAS did not confirm the previous suggestive associations observed between AN and SOX2OT or the results of candidate gene meta-analyses in regard to HTR2A and 5-HTT; thus, it is unknown whether these are potential true hits for AN or if GWAS to date have been underpowered to detect these effects.
Cross-Disorder Analysis
With the advent of GWAS and a growing repository of biological samples, it is now possible to examine shared genetic variants across disorders. These methodologies allow for identifying genetic overlap that occurs between multiple traits of interest. Although there are several novel methodologies developed to identify genetic overlap between disorders, only two have been applied to AN to date: linkage disequilibrium score regression (LDSC) and cross-trait analysis. LDSC is a statistical method used to determine the genetic correlation (r g ) between phenotypes [24••] . LDSC uses GWAS summary statistics from case and control samples, accounts for linkage disequilibrium, and is not biased by sample overlap. Crosstrait analysis simply compares whether the genetic variants in a GWAS for one phenotype (e.g., AN) were found to be associated with a second phenotype, in an independent GWAS, based on a pre-determined significance or hit threshold (e.g., the top 1000 most significant SNPs).
LDSC has been applied to examine the genetic relationship between AN and several other phenotypes. The first study, which had a relatively small GWAS AN sample available (n = 2907), observed a positive genetic correlation between AN and schizophrenia and a negative genetic correlation between AN and body mass index (BMI) [24••] . This suggests that the variants associated with schizophrenia increase risk for AN, whereas the variants associated with increased BMI decrease risk for AN. In contrast, a cross-trait analysis of risk alleles for AN and BMI showed that nine SNPs involved in risk for AN may also be associated with increased BMI [25••] . These findings suggest that the shared genetic risk for AN and BMI is complex and may involve some loci that predispose body weight in a directional manner (e.g., loci associated with propensity for lower body weight) along with others that do not function in a directional manner but may either increase or decrease body weight based on the influence of additional factors, such as the environment, as Hinney et al. suggest [25••] . Replication and further exploration of shared genetic risk for AN and BMI will shed light on the degree to which specific loci indicate directional risk or susceptibility to environmental influence on body weight.
In 2017, the largest LDSC study of AN was completed to date, which included 159 different phenotypes [21••] . Findings indicated positive genetic correlations with neuroticism, schizophrenia, educational attainment, cross-disorder psychiatric risk, and HDL cholesterol, suggesting that variants associated with these phenotypes also increase risk for AN. Negative genetic correlations with obesity, normal range BMI, and other metabolic markers (e.g., insulin resistance, fasting glucose) were also observed, indicating that variants associated with increased risk for these phenotypes also decrease risk for AN. The negative correlations between AN and insulin resistance and AN and fasting insulin were the strongest genetic correlations among all the phenotypes examined, estimated at r g = − .50 and r g = − .41, respectively [21••] . Further, the results of this study corroborate the genetic correlations in regard to AN and BMI discussed above indicating that the genetic risk for increased BMI is negatively associated with AN. The association observed between normal range BMI and AN also suggests that extremes of body weight (i.e., AN) are not necessarily regulated by genetic factors exclusive from normal variation in body weight. Going forward, examining cross-disorder associations may move beyond full-syndrome AN to explore continuous phenotypes and AN symptomatology with other psychiatric and medical phenotypes.
Future Perspectives
Family and twin studies have demonstrated a significant genetic component for AN, and more contemporary molecular methods such as GWAS have begun to identify regions of the genome and variants that contribute to AN. Still, additional methods are available that will provide new avenues for identifying genetic markers for risk including the polygenic risk score (PRS), high-throughput sequencing, and copy number variation (CNV) ( Table 1) . Integrating this newfound genetic information-using multiple genomic approaches-with environmental risk factors will be key to providing comprehensive multifactorial risk prediction models. However, none of this will be possible without collaboration among researchers.
Polygenic Risk Score
The PRS [26•] uses GWAS information from all SNPs to create an individual genetic risk profile for association with a disorder. Varying p value thresholds are examined for significance of a PRS and association with a disease in a discovery sample. The PRS derived in the discovery sample is then applied to an independent, target sample to examine the extent to which that PRS is associated with the phenotype. One advantage of this approach is that no genome-wide significance is necessary for SNPs to be included in the analyses-the analysis is on SNPs that may not necessarily meet the strict p value threshold, thus maximizing the amount of genomic data already available. Individuals from the target sample are divided into groups (e.g., quartiles) based on their PRS to examine whether individuals who are at highest genetic risk are more likely to have AN compared with individuals at lowest genetic risk. A PRS for AN is under development.
Although there are no published studies for AN using this method, it has been informative for other psychiatric disorders. For example, the PRS for schizophrenia explains nearly 18% of the genetic variation in that disorder [27] . Additional benefits of the PRS are that environmental variables can easily be included in the model (see below) and can be applied for use in other psychiatric disorders or related traits such that it is another method to examine cross-disorder associations. Specifically, PRS of AN can be applied to other psychiatric phenotypes and medical or physical traits to evaluate shared risk (and vice versa). Although the PRS has the potential to provide powerful information on genetic etiology, caution is critical when interpreting any findings. Not only will increasing sample sizes improve prediction models [27] , but it is essential that this information be coupled with additional genomic and environmental information to create more accurate multimodal risk prediction models.
High-Throughput Sequencing
Researchers have long debated whether common variants of small effect (termed common disease, common variant hypothesis) or rare variants of large effect (termed common disease, rare variant hypothesis) influence risk for psychiatric disorders. Common variants are genetic variants where the minor allele occurs in more than 5% of the population, whereas rare variants describe genetic variants in which the minor allele is present in less than 5% of the population. The genomic methods discussed herein have focused exclusively on common variants because they are easier to detect since they are present in a vast majority of individuals. On the other hand, rare variants may have higher disease penetrance, but are only present in a small number of individuals. This makes detection difficult as sample sizes on par with what is needed for GWAS are necessary. Ultimately, the findings from studies examining both hypotheses will provide the greatest insight into genetic risk for AN. High-throughput DNA sequencing is a popular method used to identify rare variants. Two common high-throughput DNA sequencing methods are exome sequencing, which sequences exons on all genes across the genome, and wholegenome sequencing, which provides an individual's entire DNA sequence. Although examining rare variants will likely yield important insight into genetic risk for AN for some individuals, this is a new direction for the eating disorder field and only three preliminary studies of AN have been published to date. The first study used a family pedigree design, which observed two mutations to segregate with AN [28] and the second a small candidate gene study design (n =~3000) observing associations between AN and two genes [29] . Although these findings show promise, studies with much larger sample sizes are necessary. The third and most recent high-throughput sequencing study of AN did not find associations between AN and common, low-frequency variants or rare variants [30] . Nevertheless, integrating information from both common and rare variants will strengthen our understanding of genetic risk for AN.
Copy Number Variation
CNV is another type of genome-wide study to examine genetic risk for disease. CNVs occur when sections of the genome are repeated or deleted and this repetition or deletion varies between individuals. In 2017, the largest CNV survey of AN was conducted [31•] . This report included approximately 2000 AN cases and examined the prevalence of rare CNVs previously associated with psychiatric and neurodevelopmental disorders. Two cases had CNVs previously associated with disease-a deletion region associated with autism, schizophrenia, and developmental delay and a deletion region previously associated with AN in a pilot study [19] . Additionally, 40 other regions containing large, rare CNVs were identified, many of which showed no previous associations with a psychiatric or neurodevelopmental disorder.
Gene and Environment Interplay
Genes and environment work jointly in the development of AN via two ways: (1) gene-environment correlation (rGE) and (2) gene-by-environment interaction (GxE) ( Table 1) . rGE occurs when environmental factors influence genetic risk for a trait. For example, an individual who has a genetic predisposition for AN may participate in weight-focused sports (e.g., gymnastics, wrestling) and/or may associate with peer groups who stress the importance of a particular body weight and shape. Unfortunately, no rGE studies in AN have been conducted.
Conversely, GxE occurs when environmental factors enhance or reduce genetic risk or when genetic risk influences response to an environment. It is more frequently discussed than rGE in AN, perhaps because it is easier to investigate in molecular genetic approaches. Modern genomic approaches are beginning to integrate specific environmental risks (e.g., childhood trauma) to determine whether having a particular genetic variant increases risk for AN in the presence of experiencing a significant life event. For example, in one small GxE study, Karwautz et al. (2011) [32•] reported that women with AN who had at least one short allele of 5-HTTLPR reported more problematic parenting styles growing up than their biological sisters who did not have AN. Although limited in scope because of the large sample sizes needed for genomic studies, studies similar to this one will undoubtedly lead to new scientific discoveries.
Collaborations and Consortiums
One lesson learned from the history of psychiatric genetics and the increasing popularity of GWAS is the need for very large sample sizes. It is now generally accepted that a minimum sample size of 10,000 cases and 10,000 controls may be necessary to find sufficient significant hits in GWAS for polygenic disease. This means the psychiatric genetics field needs to become a field of collaboration. The sample sizes necessary to find meaningful results are next to impossible for a single scientific researcher to obtain. As such, in 2007, the Psychiatric Genomics Consortium (PGC) was established. The PGC includes over 800 researchers from 38 different countries and more than 900,000 individual samples. To date, the PGC has 13 working groups representing differing areas of interest in psychiatric genetics, including eating disorders, which joined the PGC approximately 4 years ago.
Unfortunately, the eating disorders field has historically lagged behind in genetics research. The AN field is beginning to make strides, but much work is to be done. Developing the PGC Eating Disorders Working Group is a start and making further advances will depend on continued collaboration. For example, we were fortunate to be part of the largest collaboration ever aimed at identifying genes involved in AN risk: the Anorexia Nervosa Genetics Initiative (ANGI). This was a worldwide collaboration in the USA (University of North Carolina), Australia, New Zealand, Sweden, and Denmark, and will represent the largest GWAS of AN ever conducted. The future of science depends on the willingness of investigators to collaborate. Meaningful science can no longer occur in a bubble.
Clinical Implications
Although an era in which individual-level genetic information can be used for clinical care of AN has not yet arrived, that is the ultimate goal of much of this work. Despite this, basic scientific understanding of the role of genetic risk in eating disorders can be integrated into clinical practice today. One of the most pertinent implications from the currently available research is understanding, and patients and families should be provided psychoeducation in regard to the genetic etiology of AN. For example, recently, widely disseminated resources for treatment providers and patients have included statements about the role of genetics in risk for eating disorders (e.g., Truths #7 and 8 from the Academy for Eating Disorders' Nine Truths about Eating Disorders [33] ). Moreover, it is a treatment provider's responsibility to provide patients with education about all of the factors that may have played a role in the development of the illness, including genetic factors.
Providing patients and caregivers with information regarding genetic and biological underpinnings as part of our understanding of AN does present some clinical issues. One study using semi-structured interviews found that patients, in general, anticipated that genetic reframing of eating disorder etiology would reduce eating disorder stigma, whereas half of patients surveyed also anticipated that genetic framing of the disease could hamper their recovery efforts [34] . Moving forward, development of accurate, digestible clinical resources to explain genetic risk to patients, including how such factors fit into a broad conceptualization of AN risk and recovery, is necessary. Genetic information can also play a valuable role in prevention. Although we are not there yet, the ability to identify genetic markers of risk could allow for early screening in those at high risk so that intervention and prevention efforts can be focused on those who are most vulnerablestopping the disease before it starts.
Genetic correlations of AN with other traits and conditions suggest there may exist shared, overlapping genetic networks that regulate behavior. Further probing of these genetic correlations will be useful for understanding clinical approaches that might be best suited for a next generation of interventions. The use of animal models to determine genetic influences on feeding and metabolism, which is beyond the scope of this review, can improve understanding of genes that might represent novel, specific pharmacotherapeutic targets for AN. For example, pharmacological agents that address metabolic or autoimmune disease identified by GWAS and LDSC findings may represent an innovative avenue to pursue for treatment. In addition, clinical research can use PRS to examine treatment response, which will eventually provide assistance in individually tailoring treatment and prevention efforts [35•] . Findings can also be included in multifactorial risk estimation algorithms that account for other genetic factors (e.g., rare variants) and environmental risk factors to improve prediction.
Conclusion
We have learned a lot about the genetic architecture of AN over the past 3 decades. However, in order to fully understand the genetic architecture of AN, we must consider all aspects including common variation, rare variation, CNVs, crossdisorder analysis, and gene-environment interplay-all of which we know little about. Early molecular genetic techniques such as linkage and candidate gene studies have fallen out of favor for these more advanced methodologies. Despite this, meta-analyses attempting to synthesize the candidate gene literature indicate that serotonin receptor and transporter genes could be involved in the genetic etiology of AN, in particular, HTR2A and 5-HTT. However, these findings have not been replicated by more contemporary genomic methods.
The eating disorders field is starting to gain traction in modern molecular genetic techniques such as GWAS and cross-disorder analysis. The first genome-wide significant locus for risk for AN has been identified. This locus has been identified previously as involved in autoimmune disease and type 1 diabetes. Cross-disorder analyses have also suggested shared genetic risk between AN and several psychiatric, educational, and medical phenotypes-with the highest overlap observed between insulin resistance and fasting insulin. Identifying a genome-wide significant locus that associates with autoimmune disease coupled with these significant genetic correlations for metabolic indicators suggests that AN may be better conceptualized as a disorder that arises from both psychiatric and metabolic etiologies.
Indeed, results of cross-disorder analyses indicate that our current diagnostic classification system does not represent etiologically distinct disorders. The arbitrary distinctions made between psychiatric disorders themselves and between psychiatric disorders and other medical diseases (e.g., type 1 diabetes) do not account for the possibility of a shared genetic etiology. Specifically, the positive genetic correlation observed between AN and schizophrenia indicates a partially shared genetic etiology. Genetic correlations observed between AN and weight-related measures (e.g., obesity, BMI) also suggest that at least some of the genetic factors that influence normal variation in BMI and weight-dysregulation extremes (e.g., AN and obesity) are shared [24••, 25 ••]-meaning that aspects of weight that were thought to have distinct etiologies in fact overlap genetically. This overlap may involve some loci that influence weight in a directional manner (i.e., predisposing to either higher or lower body weight) and others that influence body weight based on the presence of additional factors. This hypothesis is consistent with models of psychopathology highlighting that, in some cases, genes may dispose "plasticity" of traits, rendering some individuals more malleable to environmental influences [36] . Moving forward, molecular genetic examinations of AN need to move beyond the full syndrome to explore symptom-level associations with other psychiatric-and medical-related traits in a cross-disorder manner. Results from such analyses can be formative in developing classification symptoms based on overlapping etiologies versus subjective distinctions. Finally, researchers must work with treatment providers to understand genetic findings so they can educate patients about the role of genes in the risk for AN and what this might mean for treatment and recovery. As the genetics field evolves, eventually genetic information will be directly used in the treatment for and prevention of AN.
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